MX2014002436A - Marcadores de diagnostico. - Google Patents
Marcadores de diagnostico.Info
- Publication number
- MX2014002436A MX2014002436A MX2014002436A MX2014002436A MX2014002436A MX 2014002436 A MX2014002436 A MX 2014002436A MX 2014002436 A MX2014002436 A MX 2014002436A MX 2014002436 A MX2014002436 A MX 2014002436A MX 2014002436 A MX2014002436 A MX 2014002436A
- Authority
- MX
- Mexico
- Prior art keywords
- diagnostic markers
- methylation status
- therapy based
- predicting response
- erbb2 gene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención provee métodos para predecir la respuesta a una terapia de cáncer basado en el estatus de metilación del gen de ERBB2. Un aspecto de la invención provee un método para predecir una respuesta a una terapia de inhibidor de EGFR basada en el estatus de metilación del gen de ERBB2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161529917P | 2011-08-31 | 2011-08-31 | |
PCT/US2012/053114 WO2013033380A1 (en) | 2011-08-31 | 2012-08-30 | Diagnostic markers |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2014002436A true MX2014002436A (es) | 2014-05-27 |
Family
ID=46826936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014002436A MX2014002436A (es) | 2011-08-31 | 2012-08-30 | Marcadores de diagnostico. |
Country Status (14)
Country | Link |
---|---|
US (4) | US20130084286A1 (es) |
EP (1) | EP2751285B2 (es) |
JP (1) | JP6297490B2 (es) |
KR (1) | KR20140057356A (es) |
CN (1) | CN104024432B (es) |
AU (1) | AU2012301889B2 (es) |
BR (1) | BR112014004762A2 (es) |
CA (1) | CA2845179A1 (es) |
HK (1) | HK1199475A1 (es) |
IL (1) | IL230851A0 (es) |
MX (1) | MX2014002436A (es) |
RU (1) | RU2614254C2 (es) |
SG (1) | SG2014011316A (es) |
WO (1) | WO2013033380A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9984201B2 (en) * | 2015-01-18 | 2018-05-29 | Youhealth Biotech, Limited | Method and system for determining cancer status |
JP6876304B2 (ja) * | 2016-06-10 | 2021-05-26 | 国立研究開発法人国立がん研究センター | 癌に対する薬物療法の効果の予測方法 |
EP3481403B1 (en) | 2016-07-06 | 2022-02-09 | Youhealth Biotech, Limited | Solid tumor methylation markers and uses thereof |
BR112019018272A2 (pt) | 2017-03-02 | 2020-07-28 | Youhealth Oncotech, Limited | marcadores metilação para diagnosticar hepatocelular carcinoma e câncer |
CN110511997A (zh) | 2018-05-22 | 2019-11-29 | 广州市康立明生物科技有限责任公司 | 肿瘤标志物、甲基化试剂、试剂盒及其应用 |
Family Cites Families (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4018653A (en) | 1971-10-29 | 1977-04-19 | U.S. Packaging Corporation | Instrument for the detection of Neisseria gonorrhoeae without culture |
US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
US4424279A (en) | 1982-08-12 | 1984-01-03 | Quidel | Rapid plunger immunoassay method and apparatus |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
WO1992020642A1 (en) | 1991-05-10 | 1992-11-26 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
US6033854A (en) | 1991-12-16 | 2000-03-07 | Biotronics Corporation | Quantitative PCR using blocking oligonucleotides |
GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
EP0655924A4 (en) | 1992-06-30 | 1996-09-11 | Oncologix Inc | A COMBINATION OF MONOCLONAL ANTIBODIES AGAINST erbB-2 AND METHOD FOR THEIR USE. |
CA2103323A1 (en) | 1992-11-24 | 1994-05-25 | Gregory D. Plowman | Her4 human receptor tyrosine kinase |
WO1995006137A1 (en) | 1993-08-27 | 1995-03-02 | Australian Red Cross Society | Detection of genes |
WO1995009847A1 (en) | 1993-10-01 | 1995-04-13 | Ciba-Geigy Ag | Pyrimidineamine derivatives and processes for the preparation thereof |
US5656643A (en) | 1993-11-08 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
WO1995024190A2 (en) | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
ES2109796T3 (es) | 1994-05-03 | 1998-01-16 | Ciba Geigy Ag | Derivados de pirrolopirimidilo con efecto antiproliferante. |
DK0817775T3 (da) | 1995-03-30 | 2001-11-19 | Pfizer | Quinazolinderivater |
EP0819129B1 (en) | 1995-04-03 | 2000-08-02 | Novartis AG | Pyrazole derivatives and processes for the preparation thereof |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5650415A (en) | 1995-06-07 | 1997-07-22 | Sugen, Inc. | Quinoline compounds |
MX9800215A (es) | 1995-07-06 | 1998-03-31 | Novartis Ag | Pirrolopirimidas y procesos para su preparacion. |
DK9500262U4 (da) | 1995-07-07 | 1996-10-07 | Bonus Energy As | Bundramme til vindmøllehus samt vindmølle omfattende samme |
AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
AU1441497A (en) | 1996-01-23 | 1997-08-20 | Novartis Ag | Pyrrolopyrimidines and processes for their preparation |
JP3406763B2 (ja) | 1996-01-30 | 2003-05-12 | 東レ・ダウコーニング・シリコーン株式会社 | シリコーンゴム組成物 |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
GB9603097D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline compounds |
DE19629652A1 (de) | 1996-03-06 | 1998-01-29 | Thomae Gmbh Dr K | 4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
DE19608588A1 (de) | 1996-03-06 | 1997-09-11 | Thomae Gmbh Dr K | Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
WO1997034895A1 (de) | 1996-03-15 | 1997-09-25 | Novartis Ag | NEUE N-7 HETEROCYCLYL-PYRROLO[2,3-d]PYRIMIDINE UND IHRE VERWENDUNG |
CZ295468B6 (cs) | 1996-04-12 | 2005-08-17 | Warner-Lambert Company | Polycyklické sloučeniny |
GB9607729D0 (en) | 1996-04-13 | 1996-06-19 | Zeneca Ltd | Quinazoline derivatives |
US5786146A (en) | 1996-06-03 | 1998-07-28 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
ATE308527T1 (de) | 1996-06-24 | 2005-11-15 | Pfizer | Phenylamino-substituierte triicyclische derivate zur behandlung hyperproliferativer krankheiten |
US6391874B1 (en) | 1996-07-13 | 2002-05-21 | Smithkline Beecham Corporation | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
JP2000515136A (ja) | 1996-07-13 | 2000-11-14 | グラクソ、グループ、リミテッド | プロテインチロシンキナーゼ阻害剤としての二環式ヘテロ芳香族化合物 |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
PT938486E (pt) | 1996-08-23 | 2008-03-27 | Novartis Ag | Pirrolopirimidinas substituídas e processos para a sua preparação |
ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
AU4779897A (en) | 1996-10-02 | 1998-04-24 | Novartis Ag | Fused pyrazole derivatives and processes for their preparation |
EP0929553B1 (en) | 1996-10-02 | 2005-03-16 | Novartis AG | Pyrimidine derivatives and processes for the preparation thereof |
EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
GB9621757D0 (en) | 1996-10-18 | 1996-12-11 | Ciba Geigy Ag | Phenyl-substituted bicyclic heterocyclyl derivatives and their use |
KR20000070751A (ko) | 1997-02-05 | 2000-11-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 세포 증식 억제제로서의 피리도[2,3-d]피리미딘 및 4-아미노피리미딘 |
US6329375B1 (en) | 1997-08-05 | 2001-12-11 | Sugen, Inc. | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors |
AU9805398A (en) | 1997-10-15 | 1999-05-03 | Children's Medical Center Corporation | Novel human egf receptors and use thereof |
ZA9811162B (en) * | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
US6566131B1 (en) | 2000-10-04 | 2003-05-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of Smad6 expression |
US6410323B1 (en) | 1999-08-31 | 2002-06-25 | Isis Pharmaceuticals, Inc. | Antisense modulation of human Rho family gene expression |
AU5652799A (en) * | 1998-09-18 | 2000-04-10 | Kyowa Hakko Kogyo Co. Ltd. | Method for the diagnosis of cell proliferative disease |
US6107091A (en) | 1998-12-03 | 2000-08-22 | Isis Pharmaceuticals Inc. | Antisense inhibition of G-alpha-16 expression |
US5981732A (en) | 1998-12-04 | 1999-11-09 | Isis Pharmaceuticals Inc. | Antisense modulation of G-alpha-13 expression |
US6046321A (en) | 1999-04-09 | 2000-04-04 | Isis Pharmaceuticals Inc. | Antisense modulation of G-alpha-i1 expression |
US6331393B1 (en) | 1999-05-14 | 2001-12-18 | University Of Southern California | Process for high-throughput DNA methylation analysis |
PL365999A1 (en) | 1999-05-14 | 2005-01-24 | Imclone Systems Incorporated | Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
US6180349B1 (en) | 1999-05-18 | 2001-01-30 | The Regents Of The University Of California | Quantitative PCR method to enumerate DNA copy number |
UA74803C2 (uk) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
WO2001068836A2 (en) | 2000-03-16 | 2001-09-20 | Genetica, Inc. | Methods and compositions for rna interference |
US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
KR20130056201A (ko) | 2000-05-19 | 2013-05-29 | 제넨테크, 인크. | ErbB 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석 |
US6365354B1 (en) | 2000-07-31 | 2002-04-02 | Isis Pharmaceuticals, Inc. | Antisense modulation of lysophospholipase I expression |
US6566135B1 (en) | 2000-10-04 | 2003-05-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of caspase 6 expression |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
DE10130800B4 (de) | 2001-06-22 | 2005-06-23 | Epigenomics Ag | Verfahren zum Nachweis von Cytosin-Methylierung mit hoher Sensitivität |
OA12734A (en) | 2001-12-12 | 2006-06-28 | Pfizer Prod Inc | Quinazoline derivatives for the treatment of abnormal cell growth. |
AU2003251597A1 (en) | 2002-06-19 | 2004-01-06 | Abgenix, Inc. | Method for predicting response to epidermal growth factor receptor-directed therapy |
EP1534865A4 (en) | 2002-06-26 | 2005-12-21 | Cold Spring Harbor Lab | METHODS AND COMPOSITIONS FOR DETERMINING METHYLATION PROFILES |
US8008003B2 (en) | 2002-11-15 | 2011-08-30 | Genomic Health, Inc. | Gene expression profiling of EGFR positive cancer |
WO2004063709A2 (en) | 2003-01-08 | 2004-07-29 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators |
CA2515096A1 (en) | 2003-02-06 | 2004-08-26 | Genomic Health, Inc. | Gene expression markers for response to egfr inhibitor drugs |
JP4453297B2 (ja) | 2003-05-27 | 2010-04-21 | トヨタ自動車株式会社 | 車両用遊星歯車式多段変速機 |
AU2004248140A1 (en) | 2003-05-30 | 2004-12-23 | Cedars-Sinai Medical Center | Gene expression markers for response to EGFR inhibitor drugs |
WO2005017493A2 (en) | 2003-08-15 | 2005-02-24 | Smithkline Beecham Corporation | Biomarkers in cancer |
US7004206B2 (en) | 2004-01-29 | 2006-02-28 | Viken James P | Automatic fluid exchanger |
WO2005090607A1 (en) * | 2004-03-08 | 2005-09-29 | Rubicon Genomics, Inc. | Methods and compositions for generating and amplifying dna libraries for sensitive detection and analysis of dna methylation |
JP5234734B2 (ja) | 2004-06-01 | 2013-07-10 | ジェネンテック, インコーポレイテッド | 抗体−薬物結合体および方法 |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
DE602006021142D1 (de) * | 2005-02-03 | 2011-05-19 | Gen Hospital Corp | Verfahren zur behandlung von gefitinib-resistentem krebs |
US8093011B2 (en) | 2005-03-16 | 2012-01-10 | Haley John D | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
US7851154B2 (en) * | 2005-07-22 | 2010-12-14 | Simon Daniel Spivack | GC tag-modified bisulfite genomic DNA sequencing for continuous methylation spectra |
US20070128636A1 (en) | 2005-12-05 | 2007-06-07 | Baker Joffre B | Predictors Of Patient Response To Treatment With EGFR Inhibitors |
WO2008027236A2 (en) | 2006-08-30 | 2008-03-06 | Genentech, Inc. | Multispecific antibodies |
JP2010540460A (ja) | 2007-09-24 | 2010-12-24 | トラガラ ファーマシューティカルズ,インク. | COX‐2阻害薬と抗HER2[ErbB2]抗体の混合物又はCOX‐2阻害薬とHER2[ErbB2]受容体チロシンキナーゼ阻害薬の混合物を用いた癌の治療 |
US8841268B2 (en) * | 2008-05-07 | 2014-09-23 | Sapporo Medical University | Method and kit for detection of cancer, and therapeutic agent for cancer |
TWI487712B (zh) | 2008-09-03 | 2015-06-11 | 建南德克公司 | 多重特異性抗體 |
NZ594665A (en) | 2009-03-20 | 2013-08-30 | Genentech Inc | Bispecific anti-her antibodies |
US20130143210A1 (en) * | 2009-10-28 | 2013-06-06 | Fabian Model | Method for the prognosis of ovarian carcinoma |
-
2012
- 2012-08-30 EP EP12756626.3A patent/EP2751285B2/en active Active
- 2012-08-30 JP JP2014528597A patent/JP6297490B2/ja active Active
- 2012-08-30 BR BR112014004762A patent/BR112014004762A2/pt not_active IP Right Cessation
- 2012-08-30 WO PCT/US2012/053114 patent/WO2013033380A1/en active Application Filing
- 2012-08-30 MX MX2014002436A patent/MX2014002436A/es unknown
- 2012-08-30 US US13/599,611 patent/US20130084286A1/en not_active Abandoned
- 2012-08-30 KR KR1020147007765A patent/KR20140057356A/ko active IP Right Grant
- 2012-08-30 CN CN201280053486.4A patent/CN104024432B/zh active Active
- 2012-08-30 AU AU2012301889A patent/AU2012301889B2/en not_active Ceased
- 2012-08-30 RU RU2014110895A patent/RU2614254C2/ru active
- 2012-08-30 SG SG2014011316A patent/SG2014011316A/en unknown
- 2012-08-30 CA CA2845179A patent/CA2845179A1/en not_active Abandoned
-
2014
- 2014-02-06 IL IL230851A patent/IL230851A0/en unknown
- 2014-11-24 US US14/551,528 patent/US20150086543A1/en not_active Abandoned
- 2014-12-31 HK HK14113127.3A patent/HK1199475A1/xx active IP Right Maintenance
-
2017
- 2017-06-29 US US15/638,135 patent/US20170306419A1/en not_active Abandoned
-
2019
- 2019-10-02 US US16/591,253 patent/US11261498B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
SG2014011316A (en) | 2014-06-27 |
WO2013033380A1 (en) | 2013-03-07 |
HK1199475A1 (en) | 2015-07-03 |
EP2751285B1 (en) | 2017-03-01 |
RU2614254C2 (ru) | 2017-03-24 |
EP2751285A1 (en) | 2014-07-09 |
CN104024432B (zh) | 2017-02-22 |
CA2845179A1 (en) | 2013-03-07 |
US20170306419A1 (en) | 2017-10-26 |
KR20140057356A (ko) | 2014-05-12 |
JP2014525270A (ja) | 2014-09-29 |
AU2012301889A1 (en) | 2014-03-06 |
EP2751285B2 (en) | 2020-04-01 |
JP6297490B2 (ja) | 2018-03-20 |
US20130084286A1 (en) | 2013-04-04 |
RU2014110895A (ru) | 2015-10-10 |
AU2012301889B2 (en) | 2016-04-21 |
US11261498B2 (en) | 2022-03-01 |
US20150086543A1 (en) | 2015-03-26 |
CN104024432A (zh) | 2014-09-03 |
BR112014004762A2 (pt) | 2018-06-19 |
US20200024670A1 (en) | 2020-01-23 |
IL230851A0 (en) | 2014-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL238724A0 (en) | A method to indicate the presence or absence of aggressive prostate cancer | |
HK1210230A1 (en) | Methods, kits and compositions for providing a clinical assessment of prostate cancer | |
MX2013005762A (es) | Biomarcadores para la prediccion de la eficacia de una inmunoterapia contra el cancer. | |
HK1201329A1 (en) | Method of predicting breast cancer prognosis | |
MX358117B (es) | Métodos y ácidos nucleicos para determinar el pronóstico de un sujeto con cáncer. | |
MY193914A (en) | Methods and apparatuses for predicting risk of prostate cancer and prostate gland volume | |
EP2756690A4 (en) | PROCESS FOR PROVIDING LOCATION-BASED SERVICE INFORMATION | |
BR112013027726A2 (pt) | instalação de poço submarino e método associado | |
MX2019010935A (es) | Panel de marcadores geneticos para el diagnostico de cancer colorrectal. | |
MX2014002436A (es) | Marcadores de diagnostico. | |
LT2912193T (lt) | Prognozuojami žymenys, skirti vėžio terapijoms poliamino inhibitoriumi | |
EP2686447A4 (en) | PROGNOSTIC MARKER SETS FOR PROSTATE CANCER | |
WO2013185779A3 (en) | Biomarkers for prostate cancer | |
BR112014029157A2 (pt) | carregador de pistola curvado lateralmente | |
MX2015007608A (es) | Metodos y composiciones para inhibir cnksr1. | |
PH12014502461A1 (en) | Biomarkers for iap inhibitor therapy | |
GB201204785D0 (en) | Method for determining prognosis of prostate cancer in a subject | |
EP2686445A4 (en) | METHOD FOR IDENTIFYING AN OBJECT CONTAINING NUCLEIC ACIDS | |
PT2608792T (pt) | Métodos de administração de um inibidor de egfr | |
PL393693A1 (pl) | Układ zasilania podstawy elektromagnetycznej wiertarki, zwłaszcza wiertarki elektrycznej | |
WO2013072393A3 (de) | Neues verfahren zur identifizierung von spezifischen markersequenzen für prostatakrebs | |
EP2630251B8 (en) | Method for identifying activation of transferases. | |
EP2728003A4 (en) | METHOD FOR DIAGNOSING THE TYPE OF PANCREATIC TUMOR | |
WO2012106368A9 (en) | Methods for inhibiting prostate cancer | |
UA82096U (ru) | Способ прогнозирования развития рефрактур |